Blurred Vision: What Could Be Causing It and When to Act

Why Categorizing Blurred Vision by Onset and Laterality Matters

Before listing every possible cause, recognizing the two axes that clinicians use first saves time and lives. The first axis is speed of onset (sudden vs. Gradual). The second is laterality (one eye vs. Both). A patient who woke up with painless unilateral visual loss is in a completely different risk category from someone whose glasses prescription has drifted over three years.

The American Academy of Ophthalmology's Preferred Practice Pattern guidelines state directly: "Acute, painless, monocular vision loss must be assumed to represent a vascular occlusive event until a thorough evaluation demonstrates otherwise." That single triage rule changes outcomes.

Grouping causes by these two axes helps clinicians and patients prioritize the pace of the workup from a 911 call to a routine optometry appointment.

Sudden vs. Gradual Onset

Sudden-onset blurred vision (minutes to hours) points toward vascular, neurologic, or mechanical causes: central retinal artery occlusion (CRAO), retinal detachment, vitreous hemorrhage, acute angle-closure glaucoma, or a posterior circulation transient ischemic attack (TIA). Each of these can produce irreversible damage if evaluation is delayed by even a few hours.

Gradual-onset blurred vision (weeks to years) more often reflects refractive change, cataract formation, macular degeneration, diabetic maculopathy, or dry eye disease. "Gradual" does not mean safe, but it does mean the evaluation can proceed in a structured, outpatient fashion rather than an emergency department.

One Eye vs. Both Eyes

Monocular blurring (confirmed by covering each eye in turn) strongly suggests pathology within that single eye or its optic nerve: cataract, retinal disease, ischemic optic neuropathy, or optic neuritis. Binocular blurring that persists when either eye alone is tested separately points toward a shared pathway: the optic chiasm, posterior visual cortex, systemic conditions like hyperglycemia, or uncorrected refractive error.

Refractive Errors: The Most Common Reason Vision Goes Soft

Refractive errors collectively affect an estimated 2.2 billion people globally, making them by far the most prevalent cause of reduced visual acuity, according to the World Health Organization's 2019 World Report on Vision. Myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia all blur images because light focuses in front of, behind, or at multiple points on the retina rather than precisely on it.

Diagnosis is straightforward: manifest refraction by an optometrist or ophthalmologist. Treatment is corrective lenses, contact lenses, or refractive surgery. No retinal exam is abnormal. The blur resolves immediately with the correct optical correction.

Presbyopia and Age-Related Refractive Shift

Adults over 40 commonly notice blurring specifically for near tasks. Presbyopia reflects progressive loss of crystalline lens elasticity. Reading glasses or progressive lenses correct it. The onset is gradual and bilateral, making it easy to distinguish from acute pathology.

When Refractive Error Is Not the Whole Story

A patient whose refraction improved at their last visit but whose corrected acuity has now worsened despite new glasses warrants a dilated fundus examination. Worsening best-corrected visual acuity (BCVA) signals a problem behind the lens.

Cataracts: Slow, Painless, and Treatable

Cataract formation is the gradual opacification of the crystalline lens. The Beaver Dam Eye Study found cataracts in approximately 17.2% of Americans aged 40 and older, with prevalence rising sharply above age 60. [1] Symptoms include blurring at all distances, glare around lights especially at night, and a progressive shift toward nearsightedness as nuclear density increases.

Types and Their Blur Patterns

Nuclear cataracts produce central blur and myopic shift. Posterior subcapsular cataracts cause disproportionate glare and near-vision loss. Cortical cataracts produce streaks and spokes of reduced contrast.

Slit-lamp examination identifies the type and density. Visual acuity under glare conditions (glare testing) quantifies functional impact. Surgical replacement with an intraocular lens restores acuity in over 95% of uncomplicated cases, and phacoemulsification is one of the most performed surgical procedures in the world.

Accelerated Cataract Risk

Prolonged systemic or inhaled corticosteroid use accelerates posterior subcapsular cataract formation. Patients on chronic prednisone or budesonide deserve an annual ophthalmic review.

Diabetic Retinopathy and Diabetic Macular Edema

Diabetic retinopathy is the leading cause of new blindness among working-age adults in the United States. [2] The Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) documented that after 20 years of type 1 diabetes, virtually all patients had some degree of retinopathy. Macular edema, the accumulation of fluid beneath the central retina, is the most common cause of vision loss in diabetic patients.

How Hyperglycemia Damages the Retina

Chronic hyperglycemia injures pericytes and endothelial cells in retinal capillaries. This leads to microaneurysms, intraretinal hemorrhages, hard exudates, and ultimately neovascularization in proliferative disease. Macular edema causes blurring that is typically bilateral but often asymmetric.

Optical coherence tomography (OCT) quantifies retinal thickness with sub-10-micron resolution and is now the standard for detecting and monitoring diabetic macular edema. Intravitreal injections of anti-VEGF agents (ranibizumab, aflibercept, bevacizumab) reduce central retinal thickness and improve visual acuity; the DRCR Retina Network Protocol T trial (N=660) showed that aflibercept produced a mean gain of +13.3 letters in eyes with baseline acuity <69 ETDRS letters. [3]

The GLP-1 Retinopathy Signal

Patients starting semaglutide or other GLP-1 receptor agonists for type 2 diabetes should be counseled about a specific risk. The SUSTAIN-6 cardiovascular outcomes trial (N=3,297) reported a statistically significant higher rate of diabetic retinopathy complications in the semaglutide group versus placebo (3.0% vs. 1.8%; hazard ratio 1.76, 95% CI 1.11 to 2.78; P<0.001). [4] The proposed mechanism is rapid lowering of HbA1c triggering autoregulatory changes in retinal blood flow, similar to the early worsening seen with intensive insulin therapy in the DCCT trial. Patients with pre-existing retinopathy starting any potent glucose-lowering agent should have a dilated fundus exam within three months of initiation.

Age-Related Macular Degeneration

Age-related macular degeneration (AMD) is the leading cause of irreversible central vision loss in adults over 65 in high-income countries. [5] Dry AMD progresses over years; wet (neovascular) AMD can cause rapid central distortion or scotoma over days to weeks.

Dry vs. Wet AMD

Dry AMD accounts for about 85 to 90% of cases. Drusen and retinal pigment epithelium changes cause gradual central blur. No approved pharmacologic treatment reverses dry AMD, though the AREDS2 formulation (vitamins C and E, lutein 10 mg, zeaxanthin 2 mg, zinc 80 mg, copper 2 mg) reduces progression to advanced AMD by approximately 25% in high-risk eyes compared with no supplementation. [6]

Wet AMD requires prompt anti-VEGF therapy. The VIEW 1 and VIEW 2 trials (combined N=2,457) showed that fixed monthly or quarterly aflibercept maintained visual acuity non-inferiorly to monthly ranibizumab at 52 and 96 weeks. [7]

Amsler Grid Monitoring

Patients with intermediate dry AMD should check an Amsler grid daily. New metamorphopsia (wavy lines) or a new central scotoma warrants same-week ophthalmology evaluation.

Acute Angle-Closure Glaucoma: The Painful Red-Eye Emergency

Acute angle-closure glaucoma (AACG) occurs when the trabecular meshwork is suddenly obstructed by iris apposition, causing intraocular pressure (IOP) to spike, sometimes above 50 mmHg. Classic presentation includes severe unilateral eye pain, headache, nausea, halos around lights, and blurring. The mid-dilated fixed pupil is a hallmark sign.

Permanent optic nerve damage can occur within 24 to 48 hours. Management requires immediate IOP reduction with topical beta-blockers (timolol 0.5%), alpha agonists (apraclonidine 1%), carbonic anhydrase inhibitors, and systemic acetazolamide, followed by laser peripheral iridotomy. [8]

AACG is contraindicated territory for watchful waiting.

Retinal Detachment and Vitreous Hemorrhage

A retinal detachment produces painless, sudden unilateral visual field loss often described as a curtain or shadow descending over the vision. Preceding flashes (photopsia) and a sudden shower of floaters indicate posterior vitreous detachment, which precedes rhegmatogenous detachment in most cases.

Vitreous hemorrhage, blood obscuring the vitreous cavity, causes sudden unilateral blurring that may appear as hazy smoke or a dark red tint.

Both require same-day surgical or laser evaluation. The success rate of primary scleral buckling or pars plana vitrectomy for retinal detachment exceeds 85% for anatomic reattachment, but visual outcomes correlate tightly with whether the macula was "on" (attached) at the time of repair.

Vascular Causes: CRAO, CRVO, and Ischemic Optic Neuropathy

Central Retinal Artery Occlusion

CRAO presents as sudden, painless, near-complete monocular vision loss, typically worse than 20/400. It is the ocular equivalent of a stroke. The ENVIS-IT trial explored intra-arterial thrombolysis, and while results were mixed, the 2021 American Heart Association stroke guidelines updated their recommendation to note that CRAO within 4.5 hours of onset may be considered for systemic thrombolysis in the absence of contraindications. [9] Any patient with CRAO needs an urgent TIA/stroke workup including carotid imaging and cardiac monitoring.

Central Retinal Vein Occlusion

CRVO causes less dramatic but still significant blurring, with characteristic flame-shaped hemorrhages in all four quadrants on fundoscopy. Anti-VEGF injections are first-line for CRVO-associated macular edema. The CRUISE trial (N=392) showed ranibizumab 0.5 mg produced a mean +14.9-letter gain at 6 months vs. +0.8 letters with sham. [10]

Non-Arteritic Ischemic Optic Neuropathy

Non-arteritic anterior ischemic optic neuropathy (NAION) causes sudden, usually painless altitudinal visual field loss in one eye, most often noticed on waking. No proven treatment exists. The physician must rule out the arteritic form (giant cell arteritis) because that variant responds to high-dose corticosteroids and, if untreated, affects the fellow eye in up to 25% of cases within days.

Neurologic Causes: Optic Neuritis, TIA, and Occipital Stroke

Optic neuritis, demyelinating inflammation of the optic nerve, affects primarily women aged 20 to 45. The Optic Neuritis Treatment Trial (ONTT, N=457) established that IV methylprednisolone 1 g/day for 3 days accelerates recovery compared with oral prednisone but does not change final acuity at one year. [11] Approximately 50% of patients presenting with optic neuritis develop multiple sclerosis within 15 years.

Posterior circulation TIA can cause transient bilateral blurring or a homonymous hemianopia. These episodes last minutes to under 24 hours. Any transient visual disturbance in a patient with vascular risk factors should prompt the same same-day evaluation as a motor TIA.

Occipital cortex infarction causes homonymous visual field defects that the patient may describe as blurring on one side. Brain MRI with diffusion-weighted imaging is necessary.

Systemic and Hormonal Causes of Blurred Vision

Hyperglycemia

Acute hyperglycemia changes lens osmolarity and refractive index, producing transient blurring in both eyes that resolves within days to weeks of glycemic stabilization. Patients newly diagnosed with diabetes or those with poorly controlled blood sugars should wait until HbA1c is stable before updating their glasses prescription.

Thyroid Eye Disease

Graves orbitopathy affects 25 to 50% of patients with Graves disease. [12] Blurring results from corneal exposure (due to proptosis), restrictive strabismus causing diplopia, or compressive optic neuropathy in severe cases. Selenium supplementation (200 mcg/day for 6 months) reduced clinical activity scores in the EUGOGO-selenium trial and is recommended for mild active Graves orbitopathy by European guidelines.

Hypertensive Retinopathy and Hypertensive Crisis

Severe hypertension (typically systolic above 180 mmHg) can cause retinal arteriolar spasm, flame hemorrhages, cotton-wool spots, and papilledema, all of which impair vision. Blurred vision with blood pressure in this range is a hypertensive emergency.

Medications Worth Knowing

Several commonly prescribed medications cause ocular toxicity:

• Hydroxychloroquine (used in lupus and rheumatoid arthritis): bull's-eye maculopathy with doses above 5 mg/kg/day. Annual retinal screening is recommended after 5 years.
• Tamoxifen: crystalline maculopathy and retinal toxicity, dose-dependent.
• Topiramate: acute myopia and secondary angle-closure glaucoma, sometimes within days of initiation.
• Corticosteroids: posterior subcapsular cataract and elevated IOP with prolonged use.
• Amiodarone: whorl-like corneal deposits (vortex keratopathy) causing halos and blur in most patients on long-term therapy.

Dry Eye Disease and Ocular Surface Disorders

Dry eye disease (DED) is a chronic multifactorial condition affecting approximately 16 million diagnosed adults in the United States. [13] Blurring from DED is characteristically intermittent, worsens with screen use, and improves temporarily after blinking. The TFOS DEWS II 2017 report defines DED as "a multifactorial disease of the ocular surface characterized by a loss of homeostasis of the tear film" with symptoms including visual disturbance and tear instability.

Severity-appropriate management starts with preservative-free artificial tears used four or more times daily, moves to cyclosporine 0.05% (Restasis) or lifitegrast 5% (Xiidra) for moderate disease, and may include punctal occlusion, autologous serum drops, or scleral lenses for severe cases.

Diagnostic Approach: What the Workup Looks Like Step by Step

First-Line Assessment

Every evaluation starts with best-corrected Snellen visual acuity, pupillary responses (relative afferent pupillary defect testing), and confrontation visual fields. A pinhole acuity test distinguishes refractive blur (improves through the pinhole) from media or retinal blur (does not improve).

Second-Line Testing by Suspected Category

• Slit-lamp biomicroscopy: cornea, lens, anterior chamber depth, iris configuration.
• Dilated fundoscopy: optic nerve, retinal vessels, macula, periphery.
• OCT: quantitative retinal and optic nerve fiber layer thickness.
• Visual field testing (Humphrey 24-2 or 30-2): glaucoma, neurologic defects.
• Fluorescein angiography: vascular leakage in AMD or diabetic maculopathy.
• MRI brain and orbits with gadolinium: optic neuritis, stroke, compressive lesions.
• Lab panel for systemic workup: fasting glucose, HbA1c, CBC, ESR, CRP (if giant cell arteritis suspected), thyroid-stimulating hormone.

Red Flags Requiring Same-Day Emergency Evaluation

The following symptoms combined with blurred vision require a 911 call or immediate emergency department visit, not a scheduled appointment:

1. Sudden monocular vision loss with a dense afferent pupillary defect.
2. Eye pain with nausea and a mid-dilated fixed pupil (AACG).
3. A curtain or shadow crossing the visual field.
4. Blurring with new facial droop, arm weakness, or speech difficulty (stroke).
5. Blurring with a thunderclap headache (subarachnoid hemorrhage).
6. Sudden diplopia with ptosis or a blown pupil (posterior communicating artery aneurysm).

Treatment Principles by Cause

There is no universal treatment for blurred vision. Cause-specific therapy is the only rational approach.

| Cause | First-Line Treatment | Evidence Base | |---|---|---| | Refractive error | Corrective lenses or refractive surgery | Standard of care | | Cataract | Phacoemulsification + IOL | >95% anatomic success rate | | Diabetic macular edema | Intravitreal anti-VEGF | DRCR Protocol T [3] | | Wet AMD | Intravitreal anti-VEGF | VIEW 1/2 trials [7] | | AACG | IOP-lowering drops + laser iridotomy | AAO PPP [8] | | Optic neuritis | IV methylprednisolone 1 g x 3 days | ONTT [11] | | Dry eye disease | Artificial tears, cyclosporine, lifitegrast | TFOS DEWS II [13] | | CRVO macular edema | Intravitreal ranibizumab or aflibercept | CRUISE trial [10] |